Table 1.
Two-year Inverse Probability of Censoring-Weighted Effect Estimates of Acute Gastroenteritis-related Hospitalization by Protocol, United States, 2009-2016 a,b
| Protocol | No. of events |
No. of person– years at risk |
Risk,% (95% CI) b |
Risk Difference, % (95% CI) b |
Vaccine Effectiveness (%) (95% CI) c |
|
|---|---|---|---|---|---|---|
| P1 | Unvaccinated series | 495 | 101,254 | 0.88 (0.79, 0.97) | 0.00 | |
| P2 | Partial RV5 series (1 dose) | 686 | 162,196 | 0.80 (0.62, 1.02) | −0.08 (−0.30, 0.13) | 9 (−14, 33) |
| P3 | Partial RV5 series (2 doses) | 1,124 | 323,558 | 0.61 (0.52, 0.71) | −0.27 (−0.40, −0.15) | 31 (19, 43) |
| P4 | Full RV5 series (3 doses) | 2,455 | 895,946 | 0.47 (0.45, 0.49) | −0.40 (−0.50, −0.31) | 46 (40, 52) |
| P5 | Partial RV1 series (1 dose) | 185 | 38,710 | 0.55 (0.37, 0.83) | −0.33 (−0.57, −0.08) | 37 (10, 64) |
| P6 | Full RV1 series (2 doses) | 553 | 186,040 | 0.49 (0.45, 0.54) | −0.38 (−0.49, −0.28) | 44 (36, 52) |
a
Estimates adjusted for month of birth, year of birth, gender, maternal age, number of siblings, overnight hospitalization, health plan type, network of provider type, residence in a metropolitan statistical area, and geographic region.
b
95% confidence intervals estimated using a non-parametric bootstrap (N=200).
c
Vaccine effectiveness calculated as (1 – risk ratio) x 100.
CI indicates confidence interval; RV1, rotavirus monovalent vaccine; RV5, rotavirus pentavalent vaccine.